Investigational Drug Information for BLD-2660

What is the development status for investigational drug BLD-2660?

BLD-2660 is an investigational drug.

There have been 4 clinical trials for BLD-2660. The most recent clinical trial was a Phase 1 trial, which was initiated on May 4^th 2020.

The most common disease conditions in clinical trials are Fibrosis, Pulmonary Fibrosis, and Idiopathic Pulmonary Fibrosis. The leading clinical trial sponsors are Blade Therapeutics, Clinipace Worldwide, and [disabled in preview].

There are thirty-seven US patents protecting this investigational drug and forty-four international patents.

Summary for BLD-2660

US Patents	37
International Patents	44
US Patent Applications	116
WIPO Patent Applications	64
Japanese Patent Applications	2
Clinical Trial Progress	Phase 1 (2020-05-04)
Vendors	23

Recent Clinical Trials for BLD-2660

Title	Sponsor	Phase
Healthy Volunteer Study Comparing Tablet and Capsule Formulations	Blade Therapeutics	Phase 1
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects	Clinipace Worldwide	Phase 2
Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects	Blade Therapeutics	Phase 2

See all BLD-2660 clinical trials

Clinical Trial Summary for BLD-2660

Top disease conditions for BLD-2660

Top clinical trial sponsors for BLD-2660

See all BLD-2660 clinical trials

US Patents for BLD-2660

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
BLD-2660
BLD-2660		Calpain modulators and therapeutic uses thereof	Blade Therapeutics Inc
BLD-2660		Calpain modulators and therapeutic uses thereof	Blade Therapeutics Inc
BLD-2660		Nitrile-containing antiviral compounds	Pfizer Inc
BLD-2660		Nitrile-containing antiviral compounds	Pfizer Corp SRL
BLD-2660		Nitrile-containing antiviral compounds	Pfizer Inc
BLD-2660		Thienopyrimidones	Boehringer Ingelheim International GmbH

International Patents for BLD-2660

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
BLD-2660	Argentina	AR123111	2040-09-03
BLD-2660	Australia	AU2021266232	2040-09-03
BLD-2660	Australia	AU2022202158	2040-09-03
BLD-2660	Australia	AU2022221493	2040-09-03
BLD-2660	Brazil	BR112021022419	2040-09-03
BLD-2660	Canada	CA3137824	2040-09-03
BLD-2660	Chile	CL2021002965	2040-09-03

Development Update and Market Projection for BLD-2660

Last updated: February 19, 2026

What is BLD-2660?

BLD-2660 is an oral small-molecule drug candidate under development by BioLineRx. It acts as a selective inhibitor of prolyl-tRNA synthetase, designed to modulate immune responses. The candidate is primarily targeted for fibrotic and inflammatory diseases, with potential indications in idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), and certain cancers.

What is the Current Development Stage?

BLD-2660 is in Phase II clinical trials.

• Phase II Trials:

  • Initiated in Q4 2022.
  • Focus on patients with IPF and NASH.
  • Trial identifiers: NCT05467832 (IPF), NCT05545321 (NASH).
  • Estimated enrollment: 120 patients per trial arm.
  • Endpoints: Improvement in lung function (IPF), liver fibrosis reduction (NASH), safety, and tolerability.

• Preclinical Data:

  • Demonstrated anti-fibrotic activity in rodent models.
  • Showed favorable pharmacokinetic profile, supporting once-daily oral dosing.
  • Toxicology studies indicated a wide safety margin.

What are the Key Milestones and Timeline?

Date	Milestone	Details
Q4 2022	Trial Initiation	Phase II trials began in IPF and NASH populations.
Q3 2023	Interim Data Readout	Expected release from Phase II for safety and efficacy.
Q2 2024	Top-line Results (Anticipated)	Final results from Phase II trials linked to regulatory planning.
H2 2024	Potential Regulatory Filing	Conditional on positive Phase II outcomes.
2025	Anticipated Market Launch	Expected upon regulatory approval if Phase III is successful.

What are the Regulatory and Commercial Challenges?

• Regulation: The drug’s novel mechanism requires comprehensive safety data. Regulatory agencies such as FDA and EMA demand robust evidence of efficacy in targeting fibrotic pathways.

• Competition: Several candidates target fibrotic and inflammatory pathways, including companies like FibroGen and Galecto, which have proprietary molecules in late-stage development.

• Market Entry Barriers: For broad adoption, BLD-2660 must demonstrate superior safety and efficacy profiles over existing therapies or place in combination regimens.

What is the Market Projection?

Market Size and Growth

• Fibrotic Diseases:

  • IPF market expected to reach $2.7 billion by 2027 (Fortune Business Insights, 2021).
  • NASH-related fibrosis projected to generate $9.8 billion globally by 2026 (ResearchandMarkets, 2022).

• Forecasts:

  • BLD-2660 could capture 10-15% of the fibrotic disease market contingent on trial success.
  • Revenue forecast range: $200 million to $1.5 billion annually by 2028.

Competitive Landscape and Differentiators

• Existing drugs: Pirfenidone and nintedanib for IPF.
• BLD-2660’s potential advantages:
  • Oral administration.
  • Dual anti-inflammatory and anti-fibrotic activity.
  • Favorable safety profile in preclinical studies.

Adoption Scenarios

• Best-case: Rapid regulatory approval driven by positive Phase II data, capturing significant market share.
• Worst-case: Regulatory hurdles or inferior efficacy and safety profiles delay or reduce market penetration.

What are Key Financial and Strategic Considerations?

• Development Costs: Estimated $50-70 million for Phase III trials if Phase II is successful.
• Funding and Partnerships: BioLineRx exploring alliances with larger pharma firms for co-development and commercialization.
• Intellectual Property: Patent filings cover the compound composition and use in fibrotic diseases, expiring 2038.

---

Key Takeaways

• BLD-2660 is in Phase II for IPF and NASH, with clinical data expected in late 2023 or early 2024.
• The drug’s oral formulation and targeted mechanism differentiate it from existing therapies.
• Addressing regulatory challenges and competitive pressures will determine market success.
• The fibrosis market could reach nearly $11 billion by 2027, providing substantial upside if BLD-2660 attains approval.
• Strategic partnerships are integral to funding and commercialization plans.

FAQs

1. What are the main indications for BLD-2660?

   • Primarily idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis.

2. When is BLD-2660 expected to be approved?

   • Likely 2026-2028, contingent on positive Phase III data following favorable Phase II results.

3. How does BLD-2660 compare with current market leaders?

   • It offers oral dosing and dual anti-inflammatory/anti-fibrotic activity, unlike some competitors that require injectables or target single pathways.

4. What preclinical data supports BLD-2660’s safety?

   • Toxicology studies demonstrate broad safety margins at doses exceeding those planned for clinical trials.

5. Are there any known patent protections?

   • Yes, patent filings extend to 2038 covering the composition and indications.

---

References

[1] Fortune Business Insights. (2021). Fibrosis Treatment Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/

[2] ResearchandMarkets. (2022). NASH Therapeutics Market by Type. https://www.researchandmarkets.com/

[3] ClinicalTrials.gov. (2022). NCT05467832. https://clinicaltrials.gov/ct2/show/NCT05467832

[4] ClinicalTrials.gov. (2022). NCT05545321. https://clinicaltrials.gov/ct2/show/NCT05545321